ACTIVE_NOT_RECRUITING

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Talk to us

Conditions

Obesity

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesity.

Official Title

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Quick Facts

Study Start:2019-09-26
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT03777215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men and women of all races
  2. * Capable of giving informed consent
  3. * Age 18-60 years
  4. * Body mass index (BMI) between 30-40 kg/m2
  5. * Satisfactory history and physical exam
  1. * Age ≤ 17 or ≥ 61 years
  2. * Pregnant, nursing, or postmenopausal women
  3. * Decisional impairment
  4. * Prisoners
  5. * Alcohol or drug abuse
  6. * Current smokers
  7. * Highly trained athletes
  8. * Claustrophobia
  9. * Subjects with \>5% weight change in the past 3 months
  10. * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
  11. * History of serious cardiovascular disease other than hypertension (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack).
  12. * History or presence of immunological or hematological disorders
  13. * Impaired hepatic function (aspartate aminotransferase or alanine aminotransferase levels \>2 times upper limit of normal range)
  14. * Impaired renal function (serum creatinine \>2.0 mg/dl)
  15. * Anemia
  16. * Treatment with anticoagulants (e.g. warfarin)
  17. * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
  18. * Treatment with medications influencing energy expenditure (e.g. psychostimulants)
  19. * Treatment with any investigational drug in the 1-month preceding the study
  20. * Inability to give, or withdraw, informed consent

Contacts and Locations

Principal Investigator

Amy C Arnold, PhD
PRINCIPAL_INVESTIGATOR
Pennsylvania State University College of Medicine

Study Locations (Sites)

Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
United States

Collaborators and Investigators

Sponsor: Amy Arnold

  • Amy C Arnold, PhD, PRINCIPAL_INVESTIGATOR, Pennsylvania State University College of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-09-26
Study Completion Date2026-12

Study Record Updates

Study Start Date2019-09-26
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity